News and Press

48th Union World Conference on Lung Health in Guadalajara, Mexico

ProteinLogic attended the 48th Union World Conference on Lung Health held in Guadalajara, Mexico, held on 11th-14th October 2017.  The conference theme was  ‘Accelerating Toward Elimination’. There was a focus on how to accelerate toward elimination of Tuberculosis. Numerous prominent scientists and global thought leaders emphasised the need for pro-active steps to find people with…

Read More

ProteinLogic develops a Rule-Out Test for Active TB

CAMBRIDGE, UK (2017-08-30) – ProteinLogic, a biomarker discovery company, funded by a grant by the European Union Horizon 2020 SME programme to develop a rapid point-of-care test for the diagnosis of Active Tuberculosis (TB), has achieved a significant milestone. In 2015, 10.4 million people fell ill with TB and 1.8 million died from the disease….

Read More

ProteinLogic appoints Dr Alex Betz as Chief Scientific Officer

CAMBRIDGE, UK (2016-05-03) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Alex Betz as Chief Scientific Officer to manage the scientific, research, technological and developmental operations. As a long standing non-executive director of the Company, Alex has helped set the company research and scientific priorities so that they line up with the…

Read More

ProteinLogic appoints Dr Roslin Russell as VP Bioinformatics & Computational Biology

ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Roslin Russell as Vice President of Bioinformatics & Computational Biology to bring technical expertise in the execution of the company’s R&D strategy. Before joining ProteinLogic, Roslin Russell spent eight years working for the Cambridge Institute, Cancer Research UK, as a computational biologist specialising in high-throughput…

Read More

ProteinLogic appoints Mr Damon Parkington as Assay Development & Research Scientist

ProteinLogic, the biomarker discovery and exploitation company, has appointed Mr Damon Parkington as Assay Development and Research Scientist to provide technical leadership in the development of novel immunoassays for research and to bring expertise on relevant clinical instruments to further the company’s R&D and business development strategies. Damon Parkington is an HCPC-registered Biomedical Scientist with…

Read More

ProteinLogic appoints Mr Mahesh Shah as Executive Chairman

ProteinLogic, the biomarker discovery and exploitation company, has appointed Mr Mahesh Shah (MBA) as Executive Chairman to lead the business as it expands into the TB diagnostics space. Mahesh Shah was the founder and CEO of the retail pharmacy business Nucare PLC, a company with operations in the UK as well as overseas. Under his…

Read More

ProteinLogic awarded Horizon 2020 grant by the European Commission to develop novel cancer diagnostic tests

A European Consortium of leading academic and clinical partners, including ProteinLogic, a UK based biomarker discovery company, have been awarded a grant by the European Union Horizon 2020 SME program to help harness the diagnostic power of genome sequencing in day-to-day clinical practice. ProteinLogic are pleased to announce they have been awarded €415,000 by the…

Read More

Consortium led by ProteinLogic awarded €3.58million grant by the EU Horizon 2020 SME Instrument to develop a rapid point-of-care TB test

ProteinLogic, a biomarker discovery company, and its collaborator, Biosensia, an in vitro diagnostic company have been awarded a grant by the European Union Horizon 2020 SME programme to develop a rapid point-of-care test for the diagnosis of Active Tuberculosis (TB). Almost 9m new cases of TB occur annually and there are over 1.4m deaths every…

Read More

Consortium led by ProteinLogic awarded £1.2m grant by the UK’s innovation agency, the Technology Strategy Board, to develop a rapid point-of-care TB test

CAMBRIDGE, UK (2013-11-12) – ProteinLogic, a biomarker discovery and exploitation company, Microtest Diagnostics, an in vitro diagnostic protein multiplexing company, and its collaborators have been awarded a grant by the government-backed Technology Strategy Board – the UK’s national innovation agency – to help support the development of MICROLOGIC™, a rapid point-of-care test for tuberculosis (TB)….

Read More

ProteinLogic appoints Dr Aron Rachamim as Chief Operating Officer

CAMBRIDGE, UK (2013-06-21) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Aron Rachamim as Chief Operating Officer (COO) to provide technical and business leadership in the execution of the company’s R&D and business development strategies. Aron graduated from the University of Oxford with an MPhys in Physics, following which he obtained an…

Read More